Table 3.
Gene | # of CpG | Chr. | max. β | Area | FDR P-value | Gene Ontology/Annotation |
---|---|---|---|---|---|---|
MROH6 | 13 | Chr 8 | −0.007 | PROMOTER | 3.3 x 10−[8] | IL18, body fat percentage/Variant may regulate inflammasome |
CDH24 | 4 | Chr 14 | −0.0031 | PROMOTER | 1.2 x 10−[7] | Cell morphogenesis, cell-cell junction assembly/Binds catenins, alterations implicated in several cancers |
WFIKKN2 | 20 | Chr 17 | 0.005 | PROMOTER | 1.4 x 10−[7] | Skeletal system development, TGFβ-R signalling pathway/Loss of function variant associated with glucose, haemoglobin A1c and HOMA-IR in humans |
FGFBP1 | 9 | Chr 4 | −0.0067 | GENE_BODY | 2.4 x 10−[7] | Signal transduction, cell-cell signalling/Increased gene expression associated with familial hypertension |
TMEM232 | 14 | Chr 5 | −0.013 | PROMOTER | 8.9 x 10−[6] | Membrane component/Variant associated with atopic dermatitis |
KCNG2 | 6 | Chr 18 | 0.008 | GENE_BODY | 1.1 x 10−[5] | Ion transport, regulation of insulin secretion/Regulation of neurotransmitters, heart rate, transport |
AKAP8L | 6 | Chr 19 | −0.007 | PROMOTER | 1.1 x 10−[5] | mRNA processing, mitotic chromosome condensation/Regulation of H3K4 histone methyltransferase complexes, apoptosis, DNA replication |
WIZ | 6 | Chr 19 | −0.007 | DOWNSTREAM | 1.1 x 10−[5] | Regulation of transcription, cell cycle/Aberrant methylation associated with atherosclerosis risk subtype |
SLC6A20 | 4 | Chr 3 | −0.005 | INTRON | 4.3 x 10−[5] | Amino acid transport, glycine transport/Variants associated with increased risk for diabetes, kidney transporters |
SCO2 | 6 | Chr22 | −0.005 | PROMOTER | 4.7 x 10−[5] | In utero embryonic development, copper transport/Cytochrome c oxidase assembly, mitochondrial copper delivery pathways |
Analysis adjusted for mother’s pre-pregnancy body mass index, mother’s age at delivery, child sex, maternal smoking and cell proportions. DMR, differentially methylation region; Chr, chromosome; FDR, false discovery rate; TSS, transcription start site.